

Session No.	Session Theme	No.	Name	Title of Abstract	Style	Session Date	Session Time	Allotted Time	Presentation Time	Place
PL	Plenary Session	10213	Junya Mita	FSP1 Drives Ferroptosis Resistance and an Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma	Oral	Friday September 18, 2026	13:40-14:10	13:40-13:49	Presentation: 7min. QA Time: 2min. Total: 9min.	Room 3
PL	Plenary Session	10058	Yuta Myojin	Childhood Obesity Promotes Liver Cancer Susceptibility Later in Life in Mouse Models	Oral	Friday September 18, 2026	13:40-14:10	13:49-13:58	Presentation: 7min. QA Time: 2min. Total: 9min.	Room 3
PL	Plenary Session	10124	Keisuke Okura	Intermediate- to High-Risk Subgroups of Hepatocellular Carcinoma Characterized by Recurrence-Survival Correlation after Hepatectomy	Oral	Friday September 18, 2026	13:40-14:10	13:58-14:07	Presentation: 7min. QA Time: 2min. Total: 9min.	Room 3
Free Papers 1	HBV	10198	Haruki Ichino	Nucleos(t)ide Analogs for Hepatitis B Virus Infection Differentially Regulate the Growth Factor Signaling in Hepatocytes.	Oral	Friday September 18, 2026	18:05-18:50	18:05-18:12	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 1	HBV	10094	Kazuhisa Murai	Netrin-1 Is a Novel Host Factor That Dually Inhibits HBV Entry	Oral	Friday September 18, 2026	18:05-18:50	18:12-18:19	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 1	HBV	10362	Zhaoyu Yan	RBP3 Is a Novel Host Regulator of HBV Protein Expression and Viral Replication	Oral	Friday September 18, 2026	18:05-18:50	18:19-18:26	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 1	HBV	10096	Xiaolei Jin	Multi-Locus HLA Evolutionary Divergence and Spontaneous Hbsag Seroclearance in Chronic Hepatitis B: a Longitudinal Taiwan Biobank Study	Oral	Friday September 18, 2026	18:05-18:50	18:26-18:33	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 1	HBV	10169	Sang Gyune Kim	Fibrosis Burden Outperforms HBV DNA in Predicting Hepatocellular Carcinoma and Liver-Related Outcomes in Patients with Indeterminate-Phase Chronic Hepatitis B	Oral	Friday September 18, 2026	18:05-18:50	18:33-18:40	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 1	HBV	10344	Rui Huang	Ireal-B as a Simple Risk Score for Predicting Hepatocellular Carcinoma in Untreated Indeterminate Chronic Hepatitis B Patients	Oral	Friday September 18, 2026	18:05-18:50	18:40-18:47	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10057	Sadatsugu Sakane	Serum Fibulin-3 Predicts Hepatocellular Carcinoma Development in Patients with MASLD and Post-DAA Chronic Hepatitis C	Oral	Saturday September 19, 2026	9:10-10:20	9:10-9:17	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10355	Seong Hee Kang	Protective Effect of SGLT2 Inhibitors Against Hepatocellular Carcinoma and Cirrhosis in Patients with Diabetes and Chronic Hepatitis B/C	Oral	Saturday September 19, 2026	9:10-10:20	9:17-9:24	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10123	Takuma Kaneko	AI Based Local Tumor Progression Prediction Following Hepatocellular Carcinoma Ablation	Oral	Saturday September 19, 2026	9:10-10:20	9:24-9:31	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10275	Wenzhen Ding	A Multimodal Highly Conformal Ablation Planning System for Hepatocellular Carcinoma: a Multicenter Retrospective and Prospective Study	Oral	Saturday September 19, 2026	9:10-10:20	9:31-9:38	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10003	Fujimasa Tada	Clinical Significance and Determinants of Hemorrhagic Events in Unresectable Hepatocellular Carcinoma under Atezolizumab Plus Bevacizumab Therapy	Oral	Saturday September 19, 2026	9:10-10:20	9:38-9:45	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10174	Joji Tani	Real-World Outcomes and Treatment Strategy of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: a Multicenter Study of 448 Patients	Oral	Saturday September 19, 2026	9:10-10:20	9:45-9:52	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10085	Yosuke Murata	Molecular Analysis of Circulating Tumor Cells as a Translational Biomarker for Systemic Therapy in Patients with Hepatocellular Carcinoma	Oral	Saturday September 19, 2026	9:10-10:20	9:52-9:59	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10354	Seong Hee Kang	Predictors of Hepatocellular Carcinoma in Cirrhotic Patients: the Role of Glucose Tolerance and Fasting Glycemia	Oral	Saturday September 19, 2026	9:10-10:20	9:59-10:06	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 2	Liver Cancer: Clinical Practice and Systemic Therapy	10006	Ying Nan Tsa	Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab as First-Line Systemic Therapy for Hepatocellular Carcinoma: a Real-World Study	Oral	Saturday September 19, 2026	9:10-10:20	10:06-10:13	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3

Session No.	Session Theme	No.	Name	Title of Abstract	Style	Session Date	Session Time	Allotted Time	Presentation Time	Place
Free Papers 3	HCC: Basic & Translational	10251	Xian-Yang Qin	MYCN Defines Stress-Adaptive Cell States in Hepatocellular Carcinoma	Oral	Saturday September 19, 2026	15:00-15:30	15:00-15:07	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 2
Free Papers 3	HCC: Basic & Translational	10036	Chaiyaboot Ariyachet	ZNF469 Coordinates a Metabolic Program for Collagen Synthesis by Regulating Amino Acid Transport and Biosynthetic Enzymes	Oral	Saturday September 19, 2026	15:00-15:30	15:07-15:14	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 2
Free Papers 3	HCC: Basic & Translational	10205	T Ishikawa	Lactylation Regulates Ferroptosis through METTL3 in Hepatocellular Carcinoma	Oral	Saturday September 19, 2026	15:00-15:30	15:14-15:21	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 2
Free Papers 3	HCC: Basic & Translational	10230	Yosuke Fujii	Hepatocyte-Specific <i>arid1a</i> Loss Favors Hepatocarcinogenesis under Chronic Liver Injury	Oral	Saturday September 19, 2026	15:00-15:30	15:21-15:28	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 2
Free Papers 4	Surgery, Biliary Diseases, and Other Topics	10092	Yu Saito	Beyond BR1/BR2: Defining Surgical Indications for Borderline Resectable Hepatocellular Carcinoma Using Tumour Burden and Vascular Invasion.	Oral	Saturday September 19, 2026	14:40-15:10	14:40-14:47	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 4	Surgery, Biliary Diseases, and Other Topics	10187	Sota Nakamura	Metabolic Refinement of Oncological Resectability Classification Using FDG-PET-Derived Suvmax in Resected Hepatocellular Carcinoma	Oral	Saturday September 19, 2026	14:40-15:10	14:47-14:54	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 4	Surgery, Biliary Diseases, and Other Topics	10239	Song Huy Nguyen Dinh	Long-Term Outcomes and Prognostic Factors Following Liver Resection for Hepatocellular Carcinoma	Oral	Saturday September 19, 2026	14:40-15:10	14:54-15:02	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-1	MASLD/ALD 1	10076	Eun Seok Kang	Development and Multicentre Validation of a Routine-Laboratory Model for Fibroscan-Defined Steatosis and Fibrosis Staging	Oral	Saturday September 19, 2026	15:45-16:20	15:45-15:52	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-1	MASLD/ALD 1	10340	Mohammad Ahmadullah Khan	FIB-4 False Negatives in MASLD: Clinical Phenotypes and an Augmented Triage Mode	Oral	Saturday September 19, 2026	15:45-16:20	15:52-15:59	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-1	MASLD/ALD 1	10079	Naing Naing Mon	A Conjugated Bile Acid-Extracellular Matrix Axis Characterises Fibrosis-Dominant MASLD and Steatosis-Fibrosis Discordance	Oral	Saturday September 19, 2026	15:45-16:20	15:59-16:06	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-1	MASLD/ALD 1	10102	Juhun Choi	Association between Circadian Rhythm-Disturbing Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease among Korean Adults	Oral	Saturday September 19, 2026	15:45-16:20	16:06-16:13	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-1	MASLD/ALD 1	10249	Cheng-Han Ng	Sarcopenic Obesity Is Associated with MASLD and All-Cause Mortality among Adults with Obesity	Oral	Saturday September 19, 2026	15:45-16:20	16:13-16:20	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-2	MASLD/ALD 2	10306	Yuji Ikeda	Identifying Significant Fibrosis in Health-Check MASLD: Added Value of MAF-5 in Normal ALT and Non-Obese Individuals	Oral	Saturday September 19, 2026	16:20-17:00	16:20-16:27	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-2	MASLD/ALD 2	10270	Chikako Sakai	Real-World Efficacy and Safety of Tirzepatide in Patients with T2DM and MASLD: a Prospective Cohort with Multicenter Retrospective Validation	Oral	Saturday September 19, 2026	16:20-17:00	16:27-16:34	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-2	MASLD/ALD 2	10357	Cosmas Rinaldi Adithya Lesmana	The Hidden Portal Pressure Burden in MASLD: EUS-PPG Reveals a Non-Invasive Marker and Portal Pressure Mismatch in a Prospective Pilot Cohort	Oral	Saturday September 19, 2026	16:20-17:00	16:34-16:41	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-2	MASLD/ALD 2	10132	Hideki Fujii	Role of Diabetes Mellitus and Platelet Count in Hepatocellular Carcinoma Development in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Oral	Saturday September 19, 2026	16:20-17:00	16:41-16:48	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3
Free Papers 5-2	MASLD/ALD 2	10242	Tsubasa Tsutsumi	Triglyceride-To-Hdl Cholesterol Ratio Identifies Coronary-Predominant Cardiovascular Risk in Patients with MASLD	Oral	Saturday September 19, 2026	16:20-17:00	16:48-16:55	Presentation: 5min. QA Time: 2min. Total: 7min.	Room 3

Session No.	Session Theme	No.	Name	Title of Abstract	Style	Session Date	Session Time	Allotted Time	Presentation Time	Place
Free Papers 6	Cirrhosis	10268	Keiichi Katayama	Impact of Acid-Suppressing Therapy on Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis: a Prospective Cohort Study.	Oral	Saturday September 19, 2026	16:50-17:20	16:50-16:58	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 1
Free Papers 6	Cirrhosis	10307	Zento Yamada	Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients with Cirrhosis and Hepatic Edema	Oral	Saturday September 19, 2026	16:50-17:20	16:58-17:06	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 1
Free Papers 6	Cirrhosis	10182	Takumi Tanizaki	Hypersplenism Promotes Liver Fibrosis Through a Tgf- β -Mediated Spleen-Liver Axis: a Murine Study of Splenic Macrophages	Oral	Saturday September 19, 2026	16:50-17:20	17:06-17:14	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 1
Free Papers 7	Liver Cancer: Detection and Risk Stratification	10045	Shoma Yoneda	Diagnostic Performance of Serum Methylated Somatostatin Liquid Biopsy for Hepatocellular Carcinoma: Comparison with Methylated <I>HOXA1</I> and <I>SEPT9</I>	Oral	Saturday September 19, 2026	16:50-17:25	16:50-16:58	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 2
Free Papers 7	Liver Cancer: Detection and Risk Stratification	10108	Jia-Ling Wu	Risks of Hepatocellular Carcinoma and Cause-Specific Mortality in Chronic Hepatitis B with Versus without Tyg-WC-Defined MASLD Proxy: a Nationwide Cohort Study	Oral	Saturday September 19, 2026	16:50-17:25	16:58-17:06	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 2
Free Papers 7	Liver Cancer: Detection and Risk Stratification	10121	Atsushi Yukimoto	Hepatocellular Carcinoma Following SVR in Patients with HCV Associated Cirrhosis and Stratification of Risk Factors: a Multicenter Study	Oral	Saturday September 19, 2026	16:50-17:25	17:06-17:14	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 2
Free Papers 7	Liver Cancer: Detection and Risk Stratification	10197	Katsuya Nagaoka	Bridging the Surveillance Gap in Steatotic and Alcohol-Related Hepatocellular Carcinoma	Oral	Saturday September 19, 2026	16:50-17:25	17:14-17:22	Presentation: 6min. QA Time: 2min. Total: 8min.	Room 2